BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Leqembi® (lecanemab) for the treatment ...
Can’t remember what you needed to buy when out for grocery shopping? Or need a minute to pinpoint the immediate neighbor’s ...
In the second of a Northern Advocate series, Denise Piper shines a light on how Alzheimer’s disease and other dementia types ...
An announcement from BioArctic AB Class B ( ($SE:BIOA.B) ) is now available. Health Canada has authorized Leqembi (lecanemab) for treating early ...
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease (early AD) who are apolipoprote ...
They represent a growing number of older adults contributing to medical research not because they’re sick, but because they ...
Phase 3 clinical trial results of an investigational drug has shown benefits in treating people with APOE4/4 with early ...
An 80-year-old man who lost his wife to dementia last year has praised her hospice care as "like being wrapped in a cosy ...
On a crisp autumn morning, thousands of walkers converged in Reid Park for the annual Walk to End Alzheimer’s fundraiser, ...
People hit the pavement in Greensboro on Saturday morning to walk with a purpose. Dozens of people laced up their sneakers ...
Eastern North Carolina Chapter held its annual Walk to End Alzheimer’s on Saturday in Fayetteville. More than ...
Spooky sights, scary sounds and costumed strangers are staples of Halloween, but these can create unique challenges for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback